Get Access to Gemtuzumab ozogamicin in India

Gemtuzumab ozogamicin is an antibody-drug conjugate that is recommended in the treatment of Haematological disorders. It is specifically indicated in the management of AML - acute myeloid leukemia. Mylotarg is the brand or trade name of this drug which is now commercially promoted by Pfizer. It was originally developed by Celltech and Wyeth, a collaboration that also developed other significant drugs. Mylotarg is used both in adult and paediatric patients. Gemtuzumab in India has to be imported for specific patient usage purpose

Mylotarg in India is a treatment option recommended by Haematologists who also have BMT expertise. In several cases, BMT is the ultimate treatment modality recommended and drugs like Gemtuzumab are given prior to it. As per the initial FDA approval in 2000, it was approved for the patients over sixty years. It was specific in relapsed AML. It was also approved for the usage in patients that are not fit or eligible for the standard chemotherapy. This was an accelerated approval. This drug was commercially withdrawn in 2010, due the data pointing towards increasing VOD risk in the patients on therapy. However, it was reapproved in 2017 both by the US FDA and EMA.

Gemtuzumab ozogamicin is a monoclonal antibody which is an advanced type of targeted therapy agent. It is prescribed both as a single agent as well as in combination with other chemotherapy agents. Mylotarg 4.5mg vials are commercially available in the US and Europe. Import channels are possible for Indian patients.